You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Boehringer Ingelheim
McKesson
Baxter
Medtronic

Last Updated: April 17, 2021

DrugPatentWatch Database Preview

ACTIMMUNE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for ACTIMMUNE

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University of Colorado, DenverPhase 1
IRCCS Eugenio MedeaPhase 2
University of Minnesota - Clinical and Translational Science InstitutePhase 2

See all ACTIMMUNE clinical trials

Recent Litigation for ACTIMMUNE

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
AMGEN INC. v. EMCURE PHARMACEUTICALS LTD.2018-06-28
AMGEN INC v. SANDOZ INC.2018-06-26

See all ACTIMMUNE litigation

Pharmacology for ACTIMMUNE
Ingredient-typeInterferon-gamma

Patent Text Search: US Patents for ACTIMMUNE

These patents were identified by searching patent claims

Supplementary Protection Certificates for ACTIMMUNE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CA 2020 00021 Denmark   Start Trial PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, DARUNAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, ISAER DARUNAVIR ETHANOLAT, OG EMTRICITABIN ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/17/1225 20170925
LUC00156 Luxembourg   Start Trial PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, DARUNAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, IN PARTICULAR DARUNAVIR ETHANOLATE, AND EMTRICITABINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/17/1225 20170925
C201530064 Spain   Start Trial PRODUCT NAME: COBICISTAT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/13/830; DATE OF AUTHORISATION: 20130524; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/830; DATE OF FIRST AUTHORISATION IN EEA: 20130524
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
McKinsey
Merck
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.